Simultaneous stimulation and concentration of cells

Details Simultaneous stimulation and concentration of cells Simultaneous stimulation and concentration of cells

2005-03-15

2005-03-15

Lankford, Jr., Leon B. (Department: 1651)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Method of regulating cell metabolism or physiology

C435S325000, C435S326000, C435S375000, C436S526000

Reexamination Certificate

active

06867041

ABSTRACT:
The present invention relates generally to methods for stimulating cells, and more particularly, to a novel method to concentrate and/or stimulate cells that maximizes stimulation and/or proliferation of such cells. In the various embodiments, cells are stimulated and concentrated with a surface yielding enhanced proliferation, cell signal transduction, and/or cell surface moiety aggregation. In certain aspects methods for stimulating a population of cells such as T-cells, by simultaneous concentration and cell surface moiety ligation are provided by contacting the population of cells with a surface, that has attached thereto one or more agents that ligate a cell surface moiety and applying a force that predominantly drives cell concentration and cell surface moiety ligation, thereby inducing cell stimulation, cell surface moiety aggregation, and/or receptor signaling enhancement. Also provided are methods for producing phenotypically tailored cells, including T-cells for the use in diagnostics, drug discovery, and the treatment of a variety of indications, including cancer, viral infection, and immune related disorders. Compositions of cells having specific phenotypic properties produced by these processes are further provided.

REFERENCES:
patent: 5190878 (1993-03-01), Wilhelm
patent: 5443983 (1995-08-01), Ochoa et al.
patent: 5470730 (1995-11-01), Greenberg et al.
patent: 5674704 (1997-10-01), Goodwin et al.
patent: 5735279 (1998-04-01), Klaveness et al.
patent: 5766944 (1998-06-01), Ruiz
patent: 5804442 (1998-09-01), Romet-Lemonne et al.
patent: 5837477 (1998-11-01), Germain et al.
patent: 5858358 (1999-01-01), June et al.
patent: 5888807 (1999-03-01), Palsson et al.
patent: 5942607 (1999-08-01), Freeman et al.
patent: 5962319 (1999-10-01), Ogawa et al.
patent: 5985653 (1999-11-01), Armstrong et al.
patent: 6096532 (2000-08-01), Armstrong et al.
patent: 6113901 (2000-09-01), Bluestone
patent: 6129916 (2000-10-01), Chang
patent: 6143297 (2000-11-01), Bluestone
patent: 6197298 (2001-03-01), Chang
patent: 6316257 (2001-11-01), Flyer et al.
patent: 6352694 (2002-03-01), June et al.
patent: 6355779 (2002-03-01), Goodwin et al.
patent: 20010031253 (2001-10-01), Gruenberg
patent: 20020090362 (2002-07-01), Strauss
patent: 20020182730 (2002-12-01), Gruenberg
patent: 20030039650 (2003-02-01), Gruenberg
patent: 20030134341 (2003-07-01), Gruenberg
patent: 20030134415 (2003-07-01), Gruenberg
patent: 20030170238 (2003-09-01), Gruenberg
patent: 20030175242 (2003-09-01), Gruenberg
patent: 20030175272 (2003-09-01), Gruenberg
patent: 20030194395 (2003-10-01), Gruenberg et al.
patent: 633930 (2000-04-01), None
patent: WO 9701304 (1997-01-01), None
patent: WO 9705233 (1997-02-01), None
patent: WO 9705239 (1997-02-01), None
patent: WO 0002520 (2000-01-01), None
patent: WO 03024312 (2003-03-01), None
patent: WO 03025158 (2003-03-01), None
patent: WO 03034820 (2003-05-01), None
patent: WO 03043643 (2003-05-01), None
patent: WO 03077658 (2003-09-01), None
Baroja, M.L. et al., “The Anti-T Cell Monoclonal Antibody 9.3 (Anti-CD28) Provides a Helper Signal and Bypasses the Need for Accessory Cells in T Cell Activation with Immobilized Anti-CD3 and Mitogens,”Cellular Immunology120: 205-217, 1989.
Bergstresser, P.R. et al., “T Cell-Mediated Terminal Maturation of Dendritic Cells,” inDendritic Cell in Fundamental and Clinical Immunology, Ricciardi-Castognoli (Ed.), Plenum Press, New York, 1997, pp. 65-69.
Groh, V. et al., “Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis,”Proceedings of the National Academy of Sciences100(16): 9452-9457, Aug. 5, 2003.
Lanzavecchia, A., “The Role of Dendritic Cells in the Generation of Effector and Memory T Cell Responses,” fromThe Midwinter Conference of Immunologists, Jan. 22-25, 2000, available at www.midwconfimmunol.org/Midwinter00/sessions/lanzavecchia.html.
Li, Q. et al., “Expanded Tumor-reactive CD4+T-Cell Responses to Human Cancers Induced by Secondary Anti-CD3/Anti-CD28 Activation,”Clinical Cancer Research5: 461-469, Feb. 1999.
Li, Q. et al., “Immunological Effects of BCG as an Adjuvant in Autologous Tumor Vaccines,”Clinical Immunology94(1): 64-72, Jan. 2000.
Zou, J.-P. et al., “Tumor-Bearing Mice Exhibit A Progressive Increase in Tumor Antigen-Presenting Cell Function and A Reciprocal Decrease in Tumor Antigen-Responsive CD4+T Cell Activity,”The Journal of Immunology148(2): 648-655, Jan. 15, 1992.
Bretscher, P., “The two-signal model of lymphocyte activation twenty-one years later,”Immunology Today13(2): 74-76, 1992.
Garland et al., “The use of Teflon cell culture bags to expand functionally active CD8+cytotoxic T lymphocytes,”Journal of Immunological Methods227: 53-63, 1999.
Haanen et al., “Selective Expansion of Cross-reactive CD8+Memory T Cells by Viral Variants,”J. Exp. Med.190(9): 1319-1328, Nov. 1, 1999.
Iezzi et al., “The Duration of Antigenic Stimulation Determines the Fate of Naive and Effector T Cells,”Immunity8: 89-95, Jan. 1998.
June et al., “The B7 and CD28 receptor families,”Immunology Today15(7): 321-331, 1994.
Kato et al., “Gene Transfer of CD40-Ligand Induces Autologous Immune Recognition of Chronic Lymphocytic Leukemia B Cells,”J. Clin. Invest.101(5): 1133-1141, Mar. 1998.
Krawczyk et al., “Cbl-b Is a Negative Regulator of Receptor Clustering and Raft Aggregation in T Cells,”Immunity13: 463-473, Oct. 2000.
Liebowitz et al., “Costimulatory approaches to adoptive immunotherapy,”Current Opinion in Oncology10: 533-541, 1998.
Ranheim and Kipps, “Activated T Cells Induce Expression of B7/BB1 on Normal or Leukemic B Cells through a CD40-dependent Signal,”J. Exp. Med.177: 925-935, Apr. 1993.
Ten Berge et al., “Selective Expansion of a Peripheral Blood CD8+Memory T Cell Subset Expressing Both Granzyme B andL-Selectin During Primary Viral Infection in Renal Allograft Recipients,”Transplantation Proceedings30: 3975-3977, 1998.
Bonyhadi, M. et al., “Xcellearate: An Autologous T Cell Immunotherapy Approach for Treating B-Cell Lymphocytic Leukemia (B-CLL),” inProceedings of the 42ndAnnual Meeting of the American Society of Hematology, San Francisco, Dec. 1-5, 2000, vol. 96, No. 11, part 1, ABSTRACT # 3616.
Creson, J. et al., “The Mode and Duration of Anti-CD28 Costimulation Determine Resistance to Infection by Macrophage-Tropic Strains of Human Immunodeficiency Virus Type 1 in Vitro,”Journal Of Virology, 73(11):9337-9347, Nov. 1999.
Hami, L. et al., “Xcellerate™: A Platform Process for the GMP Manufacture of Activated T Cells for the Treatment of Patients with Cancer and Immune Dysfunction,” inProceedings of the 42ndAnnual Meeting of the American Society of Hematology, San Francisco, Dec. 1-5, 2000, vol. 96, No. 11, part 1, abstract # 3630.
Kalamasz, D. et al., “Storage Shipment of Freshly Harvested or Cryopreserved Xcellerate™ Activated T Cells for Clinical Applications,” inProceedings of the 42ndAnnual Meeting of the American Society of Hematology, San Francisco, Dec. 1-5, 2000, vol. 96, No. 11, part 2, abstract # 5113.
Larsson, S. et al., “Productive Cytomegalovirus (CMV) Infection Exclusively in CD13-Positive Peripheral Blood Mononuclear Cells from CMV-Infected Individuals,”Transplantation, 65(3):411-415, Feb. 15, 1998.
Polanski, M. et al., “Xcellerate( : A Closed, Scalable Process for the GMP Manufacture of Stable Activated T Cells,” inProceedings of the 15thAnnual Scientific Meeting of the Society for Biological Therapy, Seattle, Oct. 26-29, 2000, andJournal of Immunotherapy, (23)5:599, Sep. 2000.

Affiliated with

Also associated with

Rating

Simultaneous stimulation and concentration of cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Simultaneous stimulation and concentration of cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Simultaneous stimulation and concentration of cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3437148